The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L04 | Immunosuppressants | |
| 3 | L04A | Immunosuppressants | |
| 4 | L04AC | Interleukin inhibitors | |
| 5 | L04AC18 |
| Active Ingredient | Description | |
|---|---|---|
| Risankizumab |
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine and inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines. Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| SKYRIZI 600 mg Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| SKYRIZI 75 mg / 150 mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| SKYRIZI 90 mg / 180 mg / 360 mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
